Cosentyx subcutaneous injection 300 mg pen, manufactured by Novartis Pharma, contains secukinumab (genetical recombination). This subcutaneous injection is indicated for autoimmune conditions such as moderate to severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. It has YJ code 3999439G4020 and is specified as 75mg 0.5mL per tube.
Cosentyx subcutaneous injection 300 mg pen
Need more detailed information?
Contact TASAKI PHARMA for inquiries about this medicine (English support available).
Contact us about this drug →